57th ASH Annual Meeting and Exposition (December 5-8, 2015): 901. Health Services and Outcomes Research – Non-Malignant Conditions: Venous Thrombosis and Anticoagulation

Health Services and Outcomes Research – Non-Malignant Conditions Oral and Poster Abstracts
Oral

Tangerine 1 (WF1), Level 2 (Orange County Convention Center)

Moderators:

Nicole M. Kuderer, M.D., University of Washington and Amanda M Brandow, DO, MS, Medical College of Wisconsin, Children's Research Institute

Disclosures:

Kuderer: Daiichi Sankyo: Consultancy ; Janssen: Consultancy , Membership on an entity’s Board of Directors or advisory committees , Research Funding ; Hospira: Consultancy . Brandow: NIH, ASH: Research Funding .

2:45 PM

745

Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Amin N Alpesh, MBA, MD¹^*, Allison Keshishian, MPH²^*, Lin Xie, MA, MS²^*, Onur Baser, MS, PhD^3,4^*, Kwanza Price, MPH⁵^*, Lien Vo, MPH, PharmD⁶^*, Prianka Singh, PharmD⁶^*, Amanda Bruno, MPH, PhD⁶^*, Jack Mardekian, PhD⁵^*, Wilson Tan, MRCS, MD⁵^*, Shalabh Singhal, MD⁶^*, Chad Patel, PharmD⁶^*, Kevin Odell, PharmD⁵^* and Jeffrey Trocio, MPH⁵^*

¹University of California, Irvine, CA
²STATinMED Research, Ann Arbor, MI
³STATinMED Research, New York, NY
⁴Center for Innovation & Outcomes Research, Department of Surgery, Columbia University, New York, NY
⁵Pfizer Inc., New York, NY
⁶Bristol-Myers Squibb, New York, NY

3:00 PM

746

Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism

Nathan T. Connell, M.D., M.P.H.^1,2, Gregory A. Abel, MD, MPH^2,3 and Jean M. Connors, M.D.^1,2

¹Hematology Division, Brigham and Women's Hospital, Boston, MA
²Harvard Medical School, Boston, MA
³Dana-Farber Cancer Institute, Boston, MA

3:15 PM

747

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Craig I Coleman, PharmD¹^*, Christine G Kohn, PharmD²^*, Concetta Crivera³^*, Jeff Schein³^* and W Frank Peacock, MD, FACEP⁴^*

¹School of Pharmacy, University of Connecticut, Storrs, CT
²School of Pharmacy, University of Saint Joseph, Hartford, CT
³Janssen Scientific Affairs, LLC, Raritan, NJ
⁴Emergency Medicine, Baylor College of Medicine, Houston, TX

3:30 PM

748

External Validation of a Risk Assesment Model for Bleeding Risk in Medical Patients: Findings from the Improve Investigators in a Tertiary Health System

Annie Press¹, David Rosenberg, MD, MPH²^*, Joanna Fishbein³^*, Franak Batliwalla, MPH²^* and Alex C. Spyropoulos, MD²^*

¹Hofstra North Shore-LIJ School of Medicine, Manhasset, NY
²Department of Hospital Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY
³The Feinstein Institute for Medical Research, Manhasset, NY

3:45 PM

749

Barriers to Implementation of Evidence-Based Stroke Prevention in Sickle Cell Disease: A Preliminary Study

Alyssa M Schlenz, Ph.D.¹^*, Joannie Hayes, M.D.¹^*, Martina Mueller, Ph.D.²^*, Shannon Hudson, Ph.D., R.N.²^*, Robert J. Adams, MD, MS³^* and Julie Kanter, MD⁴

¹Pediatrics, Medical University of South Carolina, Charleston, SC
²College of Nursing, Medical University of South Carolina, Charleston, SC
³Medical University of South Carolina, Charleston, SC
⁴Division of Pediatric Hematology-Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC

4:00 PM

750

Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study

Susan R Kahn, MD, MSc¹, Andrew Hirsch, MD²^*, Margaret Beddaoui, MSc³^*, Arash Akaberi, MSc³^*, David Anderson, MD⁴, Philip S Wells, MD, MSc⁵, Marc Rodger, MD, MSc⁶, Susan Solymoss, MD⁷, Michael J. Kovacs, MD⁸, Lawrence Rudski, MD⁷^*, Avi Shimony, MD⁹^*, Carole Dennie, MD¹⁰^*, Chris Rush, MD¹¹^*, William H. Geerts, MD¹², Paul Hernandez, MD⁴^*, Shawn Aaron, MD¹³^* and John T Granton, MD¹⁴^*

¹Center for Clinical Epidemiology, McGill University, Jewish General Hospital, Montreal, QC, Canada
²Department of Medicine, Jewish General Hospital, Montreal, QC, Canada
³Center for Clinical Epidemiology, Lady Davis Institute, Montreal, QC, Canada
⁴Department of Medicine, Dalhousie University, Halifax, NS, Canada
⁵Department of Medicine, The University of Ottawa, Ottawa, ON, Canada
⁶Department of Hematology, University of Ottawa, Ottawa, ON, Canada
⁷Department of Medicine, McGill University, Montreal, QC, Canada
⁸Department of Medicine, Division of Hematology, University of Western Ontario, London, ON, Canada
⁹Department of Cardiology, Ben Gurion University, Beer Sheva, Israel
¹⁰Department of Diagnostic Imaging, University of Ottawa, Ottawa, ON, Canada
¹¹Department of Nuclear Medicine, Jewish General Hospital, Montreal, QC, Canada
¹²Sunnybrook Health Sciences Centre, Department of Medicine, Toronto, ON, Canada
¹³Department of Medicine, University of Ottawa, Ottawa, ON, Canada
¹⁴Department of Medicine, University of Toronto, Toronto, Canada

See more of: Health Services and Outcomes Research – Non-Malignant Conditions
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

901.O3.6 901. Health Services and Outcomes Research – Non-Malignant Conditions: Venous Thrombosis and Anticoagulation